Effect of botulinum toxin Type A on various gait parameters in cerebral palsy with lower limb spasticity

2018 ◽  
Vol 32 (3) ◽  
pp. 169
Author(s):  
Abhimanyu Vasudeva ◽  
Nonica Laisram ◽  
AsemRangita Chanu
Keyword(s):  
Cerebral Palsy ◽  
Botulinum Toxin ◽  
Lower Limb ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Gait Parameters ◽  
Limb Spasticity ◽  
Lower Limb Spasticity

scholarly journals Botulinum Toxin Type A Improves Function According to Goal Attainment in Adults with Poststroke Lower Limb Spasticity in Real Life Practice

2019 ◽  
Vol 82 (1-3) ◽  
pp. 1-8 ◽  
Author(s):  
Lourdes López de Munain ◽  
Josep Valls-Solé ◽  
Irene Garcia Pascual ◽  
Pascal Maisonobe ◽  
Keyword(s):  
Botulinum Toxin ◽  
Lower Limb ◽  
Goal Attainment ◽  
Botulinum Toxin Type A ◽  
Real Life ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Goal Achievement ◽  
Limb Spasticity ◽  
Lower Limb Spasticity

Introduction: Botulinum toxin type A (BoNT-A) is an effective and well-tolerated treatment for adult lower limb spasticity. However, data are inadequate to determine BoNT-A efficacy for active function. This study evaluated functional goal achievement (measured by goal attainment scaling [GAS]) following lower limb BoNT-A injection in clinical practice. Methods: Phase 4, postmarketing, multicenter, prospective, observational study (NCT01444794) in adults with poststroke lower limb spasticity receiving one BoNT-A injection cycle. Assessments were at baseline (pretreatment), 1 month ±7 days (visit 1), and 3–5 months posttreatment (visit 2). Primary outcome measure was GAS; additional assessments included Modified Ashworth Scale, Demeurisse Motricity Index, 10-meter walk test, and Disability Assessment Scale. Results: Of 100 enrolled patients, 94 completed the study. Most common primary treatment goals at baseline were improving mobility (57.5%) and positioning (18.1%). At visit 2, 88.3% achieved their primary goal; 87.0% (n = 47/54) for mobility, and 100.0% (n = 17/17) for positioning. In total, 79.1% of patients achieved their secondary goals. Two factors were predictive of primary goal achievement: time since stroke onset (OR 0.907; 95% CI 0.827–0.995; p = 0.038); and absence of stiff knee spasticity pattern (OR 0.228; 95% CI 0.057–0.911; p = 0.036). All functional scales showed improvements; walking speed (mean [SD]) improved by 0.06 (0.13) and 0.05 (0.20) m/s at visits 1 and 2, respectively. Conclusions: BoNT-A injection for lower limb spasticity led to high goal achievement rates in patient-centered GAS evaluation and functional and symptomatic improvements. BoNT-A may therefore deliver clinically meaningful functional improvements in real-life practice.

Analysis of 1-year department activity when treating lower limb spasticity poststroke with botulinum toxin type A

Toxicon ◽  
2018 ◽  
Vol 156 ◽  
pp. S101
Author(s):  
Mariana Santiago ◽  
Helena Tavares ◽  
Maria José Festas ◽  
Fernando Parada
Keyword(s):  
Botulinum Toxin ◽  
Lower Limb ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Limb Spasticity ◽  
Lower Limb Spasticity

Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke

Drugs ◽  
2019 ◽  
Vol 79 (2) ◽  
pp. 143-160 ◽  
Author(s):  
Andrea Santamato ◽  
Nicoletta Cinone ◽  
Francesco Panza ◽  
Sara Letizia ◽  
Luigi Santoro ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Lower Limb ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Limb Spasticity ◽  
Lower Limb Spasticity
Sign in / Sign up

Export Citation Format

Share Document